WuXi Biologics and Sartorius Stedim Biotech open joint laboratory in Shanghai
Certified leading upstream platform powers China’s biopharmaceutical development.
Sartorius Stedim Biotech and WuXi Biologics have opened their Joint Laboratory in Shanghai, marking an exciting new stage in their long-term cooperation. The Joint Laboratory has been established to enhance China’s position in the global R&D of novel biologics and to facilitate more biologics to enter pilot studies and manufacture. As a result, this lab will help improve the capability and quality of biologics R&D in China and further provide more effective biologics for patients around the world.
“As the upstream leader and pharmaceutical companies’ partner, Sartorius will strongly support the rapid expansion of the Chinese biopharmaceutical industry through ‘speed to clinic, increased titers, quality by design, and robust production," said Dr Joerg Lindenblatt, the Senior Vice President for Asia at Sartorius Stedim Biotech. "Cooperation between WuXi Biologics and Sartorius is based in China, but has a global perspective. Both parties share the same concepts on innovation and quality and have the same pursuit of global business development. I believe this Joint Laboratory will lay the foundation for sustainable development of both parties, accelerate the implementation of innovative technologies and solutions in a faster and broader way, and further benefit biopharmaceutical companies in the world.” "WuXi Biologics is devoted to building the leading ONE-stop service platforms for biologics R&D and manufacture and to providing comprehensive services for biopharmaceutical clients throughout the world,” said Dr Chris Chen, CEO of WuXi Biologics. “Collaboration with Sartorius is part of our effort to introduce innovative research concepts and world-leading technology platforms, which will shorten our time on biologics development, accelerate the biologics R&D process from concept to commercialization, lower the cost of biologics R&D and benefit patients around the world.” The Joint Laboratory is equipped with leading-edge single-use platforms including SSB's high-throughput ambr 15 and ambr 250, BIOSTAT STR single-use bioreactors and a single-use media/buffer preparation station. ambr is an automated, high-throughput microscale bioreactor system used by most of the international biopharmaceutical companies for their early stage R&D and process optimization, and supports accelerated development, optimization and rapid scale-up of cell culture processes.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance